1. Myeloid ALX/FPR2 regulates vascularization following tissue injury
- Author
-
Michael J. Zhang, Andreas Patsalos, Blenda Wong, Laszlo Nagy, Brian E. Sansbury, Nikolas Giannakis, Xiaofeng Li, and Matthew Spite
- Subjects
Male ,Docosahexaenoic Acids ,Transcription, Genetic ,medicine.medical_treatment ,Primary Cell Culture ,Ischemia ,Neovascularization, Physiologic ,Endogeny ,Revascularization ,Gene Knockout Techniques ,Mice ,medicine ,Animals ,Humans ,RNA-Seq ,Receptors, Lipoxin ,Muscle, Skeletal ,Receptor ,Cells, Cultured ,Skin ,Mice, Knockout ,Wound Healing ,Multidisciplinary ,business.industry ,Macrophages ,Skeletal muscle ,Lipid signaling ,Biological Sciences ,medicine.disease ,Receptors, Formyl Peptide ,Phenotype ,Cell biology ,Disease Models, Animal ,medicine.anatomical_structure ,Female ,business ,Perfusion ,Signal Transduction - Abstract
Ischemic injury initiates a sterile inflammatory response that ultimately participates in the repair and recovery of tissue perfusion. Macrophages are required for perfusion recovery during ischemia, in part because they produce growth factors that aid in vascular remodeling. The input signals governing this pro-revascularization phenotype remain of interest. Here we found that hindlimb ischemia increases levels of resolvin D1 (RvD1), an inflammation-resolving lipid mediator that targets macrophages via its receptor, ALX/FPR2. Exogenous RvD1 enhances perfusion recovery during ischemia, and mice deficient in Alx/Fpr2 have an endogenous defect in this process. Mechanistically, RNA sequencing revealed that RvD1 induces a transcriptional program in macrophages characteristic of a pro-revascularization phenotype. Vascularization of ischemic skeletal muscle, as well as cutaneous wounds, is impaired in mice with myeloid-specific deficiency of Alx/Fpr2 , and this is associated with altered expression of pro-revascularization genes in skeletal muscle and macrophages isolated from skeletal muscle. Collectively, these results uncover a role of ALX/FPR2 in revascularization that may be amenable to therapeutic targeting in diseases associated with altered tissue perfusion and repair.
- Published
- 2020
- Full Text
- View/download PDF